Boardroom Alpha
Boardroom Alpha
BEAT · Current Report (Form 8-K) · Filed August 3, 2026

Heartbeam Inc — Current Report (Form 8-K)

Form
8-K
Filed
August 3, 2026
Period
Jul 31, 2026
Ticker
BEAT
Accession
0001213900-26-084622
Boardroom Alpha · Filing insights

The proposed increase in authorized shares under the 2022 Equity Incentive Plan was not approved; seven directors were elected.

About Heartbeam Inc
Market cap
$28M
1Y TSR
−53.1%
3Y TSR
−40.2%
Board grade
C-
Sector
Healthcare
CEO
Branislav Vajdic
Last annual meeting: Jul 31, 2026 · View full Heartbeam Inc profile →

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 31, 2026

 

HEARTBEAM, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-41060   47-4881450
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

2118 Walsh Avenue, Suite 210

Santa Clara, CA 95050

(Address of principal executive offices, including zip code)

 

(408) 899-4443

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   BEAT   NASDAQ
Warrant   BEATW   NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On July 31, 2026, HeartBeam, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”) virtually, via live webcast.

 

As of the close of business on June 5, 2026, the record date for the Annual Meeting (the “Record Date”), 55,506,835 shares of the Company’s common stock, par value $0.0001 (the “Common Stock”) were outstanding and entitled to vote. At the Annual Meeting, a total of 29,050,272 votes, comprised of shares of the Company’s Common Stock, equivalent to approximately 52.34% of the outstanding votes, were represented in person or by proxy at the Annual Meeting, constituting a quorum. The matters that were voted upon at the Annual Meeting, and the number of votes cast for or against/withheld, as well as the number of abstentions and broker non-votes, as to such matters, where applicable, are set forth below.

 

1. The seven nominees for director were elected to serve a one-year term as follows:

 

Director   Votes For   Votes Against   Abstain   Broker
Non-Vote
Richard Ferrari   10,429,353   1,297,635   89,264   17,234,020
Branislav Vajdic, PhD   10,867,830   861,433   86,989   17,234,020
George A. de Urioste   10,579,015   1,044,127   193,110   17,234,020
Marga Ortigas-Wedekind   10,552,293   1,163,639   100,320   17,234,020
Willem Elfrink   10,439,928   1,286,668   89,656   17,234,020
Kenneth Nelson   10,762,731   964,258   89,263   17,234,020
Michael Jaff   10,760,673   1,017,128   38,451   17,234,020

 

2. The proposal to ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was approved as follows:

 

Votes For   Votes Against   Broker Non-Votes   Votes Abstained
28,612,850   173,008   0   264,414

 

3. The proposal to amend the 2022 Equity Incentive Plan to increase the number of authorized shares by 3,000,000 shares was not approved as follows:

 

Votes For   Votes Against   Broker Non-Votes   Votes Abstained
3,957,529   7,816,794   17,234,020   41,929

 

1
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  HeartBeam, Inc.
     
Date: August 3, 2026   /s/ Timothy Cruickshank
  Name:  Timothy Cruickshank
  Title: Chief Financial Officer

 

2

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Heartbeam Inc (BEAT)

Reference

Frequently asked questions

When did Heartbeam Inc file this 8-K?
Heartbeam Inc (BEAT) filed this Current Report (Form 8-K) with the SEC on August 3, 2026. The accession number assigned by EDGAR is 0001213900-26-084622.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
The proposed increase in authorized shares under the 2022 Equity Incentive Plan was not approved; seven directors were elected. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Heartbeam Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Heartbeam Inc has filed under CIK 1779372, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer